Association of Missense Polymorphism inHSD3B1With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone | Zendy

Masaki Shiota | Zendy; Shintaro Narita | Zendy; Shusuke Akamatsu | Zendy; Naohiro Fujimoto | Zendy; Takayuki Sumiyoshi | Zendy; Maki Fujiwara | Zendy; Takeshi Uchiumi | Zendy; Tomonori Habuchi | Zendy; Osamu Ogawa | Zendy; Masatoshi Eto | Zendy

Open Access

Association of Missense Polymorphism inHSD3B1With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone

Author(s) -

Masaki Shiota,

Shintaro Narita,

Shusuke Akamatsu,

Naohiro Fujimoto,

Takayuki Sumiyoshi,

Maki Fujiwara,

Takeshi Uchiumi,

Tomonori Habuchi,

Osamu Ogawa,

Masatoshi Eto

Publication year - 2019

Publication title -

jama network open

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.278

H-Index - 39

ISSN - 2574-3805

DOI - 10.1001/jamanetworkopen.2019.0115

Subject(s) - prostate cancer , androgen deprivation therapy , medicine , oncology , interquartile range , hazard ratio , cohort , genotype , progression free survival , abiraterone , cancer , androgen receptor , biology , overall survival , confidence interval , genetics , gene

This prognostic study investigates the significance of missense polymorphism in the HSD3B1 gene among men treated with primary androgen-deprivation therapy or abiraterone for prostate cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research